The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma-Reference-Cited by-同舟云学术

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma

Published:2008-03 Issue:3 Volume:19 Page:553-559
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Overman M.J.,Feng L.,Pro B.,McLaughlin P.,Hess M.,Samaniego F.,Younes A.,Romaguera J.E.,Hagemeister F.B.,Kwak L.,Cabanillas F.,Rodriguez M.A.,Fayad L.E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/19/3/553/684219/mdm511.pdf

Reference31 articles.

1. Non-Hodgkin's Lymphoma;Armitage,2001

2. Follicular lymphoma international prognostic index;Solal-Celigny;Blood,2004

3. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project [editorial];N Engl J Med,1993

4. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma;Martin;Blood,1995

5. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project [editorial];Cancer,1982

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of immunochemotherapy with R‐bendamustine or R‐CHOP for treatment naïve advanced‐stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi;Hematological Oncology;2023-05-28

2. Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy;Leukemia & Lymphoma;2019-04-03

3. Follicular large cleaved cell (centrocytic) lymphoma: an unrecognized variant of follicular lymphoma;Human Pathology;2018-02

4. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP;Clinical Lymphoma Myeloma and Leukemia;2018-01

5. Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy;Clinical Lymphoma Myeloma and Leukemia;2017-08